Please provide your email address to receive an email when new articles are posted on . There was a substantial uptake in the use of alternative filgrastim products, including its biosimilar ...

With the increasing emergence of less expensive biologic alternatives, some health systems are making the switch. For a large healthcare system, the arrival of a cheaper alternative to filgrastim ...

Previous studies have found modest uptake of biosimilars in both commercial and Medicare populations. This study finds that the uptake varies between the rural and urban provider settings. Biosimilars ...

Referring physicians are a major reason why patients do not enroll in office-based clinical trials This is an ASCO Meeting Abstract from the 2005 ASCO Annual Meeting. This abstract does not include a ...

The recent FDA approval of Aphexda combined with filgrastim improved the collection of stem cells in patients with multiple myeloma. Stem cell transplantation is an important treatment method for ...

Biologics used to treat patients can be incredibly expensive, so there was significant hope that biosimilar drugs -- which are highly similar to an existing biologic drug on the market -- could serve ...

The use of biosimilar biologics filgrastim-sndz and tbo-filgrastim increased substantially among Medicare beneficiaries between 2014 and 2016, according to a research letter published in JAMA. The ...